A

ANI Pharmaceuticals
D

ANIP

57.990
USD
-1.75
(-2.93%)
مغلق
حجم التداول
4,462
الربح لكل سهم
6
العائد الربحي
-
P/E
-123
حجم السوق
1,218,820,772
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CAH
    -0.340
    (-0.27%)
    127.080 USD
    H
    HSIC
    -0.820
    (-1.05%)
    77.255 USD
    I
    ICLR
    -0.340
    (-0.17%)
    201.310 USD
    IDXX
    IDXX
    -0.33
    (-0.07%)
    452.66 USD
    L
    LH
    0.655
    (0.26%)
    249.865 USD
    P
    PAHC
    -0.510
    (-2.22%)
    22.460 USD
    P
    PRGO
    0.090
    (0.36%)
    25.340 USD
    ZBH
    ZBH
    1.250
    (1.21%)
    104.890 USD
    ZTS
    ZTS
    3.090
    (1.96%)
    160.480 USD
    المزيد
الأخبار
المقالات

العنوان: ANI Pharmaceuticals

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.